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Cachexia is strongly associated with a poor prognosis in cancer patients but the
biological trigger is unknown and therefore no therapeutics exist. The loss of skeletal
muscle is themost deleterious aspect of cachexia and it appears to depend on secretions
from tumor cells. Models for studying wasting in cell culture consist of experiments where
skeletal muscle cells are incubated with medium conditioned by tumor cells. This has
led to candidates for cachectic factors but some of the features of cachexia in vivo are
not yet well-modeled in cell culture experiments. Mouse myotube atrophy measured by
myotube diameter in response to medium conditioned by mouse colon carcinoma cells
(C26) is consistently less than what is seen in muscles of mice bearing C26 tumors with
moderate to severe cachexia. One possible reason for this discrepancy is that in vivo
the C26 tumor and skeletal muscle share a circulatory system exposing the muscle to
tumor factors in a constant and increasing way. We have applied Transwell®-adapted
cell culture conditions to more closely simulate conditions found in vivo where muscle
is exposed to the ongoing kinetics of constant tumor secretion of active factors. C26
cells were incubated on a microporous membrane (a Transwell® insert) that constitutes
the upper compartment of wells containing plated myotubes. In this model, myotubes
are exposed to a constant supply of cancer cell secretions in the medium but without
direct contact with the cancer cells, analogous to a shared circulation of muscle and
cancer cells in tumor-bearing animals. The results for myotube diameter support the
idea that the use of Transwell® inserts serves as a more physiological model of the
muscle wasting associated with cancer cachexia than the bolus addition of cancer cell
conditioned medium. The Transwell® model supports the notion that the dose and
kinetics of cachectic factor delivery to muscle play a significant role in the extent of
pathology.
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BACKGROUND
Cachexia is a devastating consequence of cancer in ∼50%
of patients (Tisdale, 2009). It is characterized by elevated
metabolism and whole body wasting that is not reversed by
feeding (Fielitz, 2016). The loss of skeletal muscle causes the
most deleterious health consequences such as weakness, fatigue,
metabolic instability, and therefore, an inability to tolerate
medical treatment (Tisdale, 2009). Muscle loss in cancer cachexia
has received more attention recently as it becomes clear that it
is the best indicator of a poor prognosis (Martin et al., 2013).
However, our understanding of the mechanisms underlying
cancer cachexia is in its infancy, and currently no treatment
exists.
One consensus of the etiology of cachexia is that it is initiated
and/or maintained by secretions from the cells of the tumor
(Coletti et al., 2006; Fearon et al., 2012; Fielitz, 2016). Therefore,
many investigations have been carried out to determine the
factor/s from different tumor cells that contribute to wasting.
Among the many models for these studies are cell culture
experiments in which cachexia target cells, such as skeletal
muscle, are incubated with medium conditioned by tumor cells
(Penna et al., 2016). Therefore, cancer cell conditioned medium
(CM) treatment of target cells has been used as an in vitro
approach to study the mechanism of wasting in muscle cells
(Zhang et al., 2011; Puppa et al., 2014; Silva et al., 2015; Bohnert
et al., 2016; Fukawa et al., 2016).
Results from studies using conditionedmedium to understand
the mechanism of myotube atrophy have shown involvement
of a number of cancer cell secreted factors (TNFα, IL-6, LIF),
and target cell signaling proteins and transcription factors such
as C/EBPβ, C/EBPδ, STAT3, P38 (Zhang et al., 2011; Puppa
et al., 2014; Seto et al., 2015; Silva et al., 2015; Bohnert et al.,
2016; Fukawa et al., 2016). Differences in the molecules found
to be involved in the mechanism of wasting are likely due to
the tumor type (Penna et al., 2016). In an in-depth study, use of
conditioned mediummade from the commonly used C26 mouse
tumor cell line led to the identification of LIF as the secreted
peptide required for myotube atrophy (Seto et al., 2015). We
showed that LIF was acting through the JAK2/STAT3 pathway
to effect atrophy. These data were consistent with what we found
in mice harboring C26 tumors. In cell culture, LIF from the C26
cells was entirely responsible for the atrophy effect of cancer cell
conditioned medium on C2C12 myotubes.
Although, secretions from tumor cells have been useful to
identify factors involved in muscle wasting, some of the features
of cachexia in vivo are not yet well-modeled in cell culture (Penna
et al., 2016). For instance, mouse myotube atrophy measured by
myotube diameter in response to C26 CM is consistently less than
what is seen bymuscle cross-sectional area inmice withmoderate
to severe cachexia where the C26 tumor and muscle share a
circulatory system (Bonetto et al., 2011; Cornwell et al., 2014;
Seto et al., 2015). In addition, serum levels of LIF in cachectic
C26 tumor-bearing mice were relatively less than that used in the
cell culture model, yet muscle atrophy was greater (Seto et al.,
2015). We wondered whether the modification of cell culture
conditions to more closely simulate conditions found in vivo
where muscle is exposed to ongoing kinetics of constant tumor
secretion of active factors might improve cell culture models.
Therefore, the purpose of this study is to determine the extent
and progression of myotube atrophy due to 3 days exposure to
secretions fromC26 tumor cells delivered as a bolus as commonly
used in conditioned medium studies, compared to myotubes
plated in a well containing cancer cells in an upper compartment
of the well. That is, C26 cells were incubated on a microporous
membrane (a Transwell R© insert, see Renaud and Martinoli,
2016) that constitutes the upper compartment of wells containing
plated myotubes. In this latter model, myotubes are exposed to
a constant supply of cancer cell secretions in the medium but
without direct contact with the cancer cells, analogous to a shared
circulation of muscle and cancer cells in tumor-bearing animals.
Therefore, the use of a Transwell R© plate, although perhaps not
recreating the volume of shared fluid, should recapitulate the
delay for tumor cell secretion and binding of cachectic factors
to myotubes. In fact, the results support the idea that the use of
Transwell R© inserts serves as a more physiological model of the
muscle wasting associated with cancer cachexia than the use of
cancer cell conditioned medium as is customarily used.
MATERIALS AND METHODS
Cells
C2C12 cells were from ATCC and used within the first 15
passages. C26 mouse adenocarcinoma cells were obtained from
the National Cancer Institute (Frederick, MD). Ehrlich tumor
cells were obtained from ATCC. All cell culture reagents were
from Invitrogen, Carlsbad, CA, USA.
Media and Cell Culture
Cancer cells were plated and maintained at 37C, 5% CO2 in
Dulbecco’s Modified Eagle Medium, high glucose (supplemented
with 10% fetal bovine serum, 1% penicillin-streptomycin, and
1% L-glutamine). C2C12 cells were serially cultured in the same
medium. Differentiation medium (DM) was used for making
conditioned medium from the tumor cells and for differentiating
the C2C12 cells. DM consisted of DMEM with 2% horse serum
with antibiotics and glutamine.
Conditioned Medium (CM) Collection
Tumor cells were grown in culture medium as described. Once
the plates reached a confluency of >90%, the growth medium
was removed, and the cells were washed twice with sterile PBS
and incubated in DM. CM was collected in DM on the tumor
cells because the Transwell R© plates were going to be cultured in
DM to maintain differentiation of the C2C12 myotubes in the
wells. After 24 h, the medium was collected and centrifuged in 50
ml falcon tubes at 4,500 rpm for 15 min in 4◦C. Aliquots of the
cell-cleared medium were stored at−80 C for up to a year.
Treatment of Myotubes with CM
C2C12 myoblasts in growth serum were plated on a 6-well plate
at a density of 5× 105 cells/well and left for overnight attachment.
The medium was then switched to differentiation medium, and
the cells were differentiated for 4 days. Conditioned medium
treatments were begun at a dilution of 33% CM in DM. Controls
were with DM alone. At the beginning and end of each of three
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24 h periods, medium was sampled for LIF measurement and
photographs were taken for determining myotube diameters. At
each 24 h interval after that, the plates were again photographed
and medium sampled and the medium was replaced with fresh
control or tumor cell-conditioned media.
Transwell® Insert Protocol
The Transwell R© system for all experiments consisted
of Costar #3450 6-well plates with 0.4 micron porous
inserts made of tissue culture treated polystyrene
(https://www.corning.com/worldwide/en/products/life-sciences/
products/permeable-supports/transwell-snapwell-netwell-falcon
-permeable-supports.html). C2C12 cells were plated onto the
bottom of the wells in the 6-well plate in the same way as
for the CM treatments and then differentiated for 4 days.
Tumor cells were plated onto the inserts in separate 6-well
plates from those with the C2C12 cells. The tumor cells were
approximately confluent at the time that the C2C12 myotubes
were differentiated. The medium for the tumor cells on the
Transwells was changed to DM for the last 2 days of culture
before adding the insert wells to the myotube 6-well plates.
Therefore, on day 4 of differentiation the myotube wells were
photographed as for the CM treatment experiments and all
medium was replaced with DM and the insert wells were placed
above differentiated myotube wells. This was called day 0.
Medium was sampled from the lower chamber at 0 h and at 1,
2, 4, 8, 12, and 24 h later. The sampling for Transwells was more
frequent than for the CM experiments in order to be sure of the
kinetics of LIF movement from the upper to lower chambers.
The medium was changed at 24 and 48 h and the same sampling
was done for each 24 h period and also photographs of the
myotube wells were made daily for 3 days. Note: Tumor cells are
normally grown in DMEM with 10% FCS, but they also grow
well in less serum (i.e., DM).
Myotube Diameter Measurement
At each time of myotube photography, 20X magnified phase
micrographs were taken. Using a Nikon TS-5000 inverted
microscope coupled with a Spot RT camera and Spot Software
(Diagnostic Instruments), seven photos of each well were taken.
The diameter of each myotube was an average of 3 measurements
along the cell and at least 150 myotubes were measured per
group (time point and treatment) using MetaMorph Imaging
software (Universal Imaging). These data were coupled to excel
spreadsheets and graphed using Prism software.
ELISA
The ELISA for mouse LIF was from R&D (Minneapolis, MN,
USA) and was performed according to the manufacturer’s
protocol.
Statistics
For one variable analysis, an unpaired t-test was used to
determine statistical difference at each time point. Data are
expressed as means± SEM, and statistical difference was defined
at P < 0.05 as noted in the figure legends.
RESULTS
LIF Levels in the Medium of Myotube
Cultures Treated with Bolus Delivery of C26
CM or with C26 Cells Plated in a
Transwell® Insert
The conventional experimental approach for treatment of 4-day
myotubes with medium conditioned by cancer cells added as
a bolus and diluted in differentiation medium (DM) is shown
in a schematic diagram (Figure 1A). In comparison, myotubes
cultured in a well that also contains cancer cells seeded on a
Transwell insert is shown schematically and photographically
(Figures 1B,C). In each case, the medium was changed every 24
h. Medium was sampled for measuring secreted LIF at intervals
described in section Materials and Methods.
A mouse specific ELISA was used to measure LIF levels
in myotube cultures containing added cancer cell CM and in
myotube cultures incubated with Transwell R© inserts containing
cancer cells. LIF levels in myotube cultures treated with one
third volume of C26 CM had concentrations of 530 pg/ml at the
beginning of a 24 h period of treatment and 370 pg/ml at the end
of the 24 h period, immediately before the medium was changed
(Figure 1D). Similar values were found at the beginning and end
of the 48 and 72 h treatment periods in CM-treated myotube
cultures (Figure 1D). The loss of LIF over the three 24 h periods
was 30, 36, and 45% with the decrease likely due to the increasing
area of unfused C2C12 cells growing in the wells, which was able
to deplete more LIF during each incubation.
By comparison, in myotube cultures containing Transwells,
LIF levels were not detectable at 0 and 1 h after incubation with
Transwell R© inserts containing C26 cells (Figure 1E). However,
after 2 h of incubation, LIF levels were 7 pg/ml and then
increased linearly to 110 pg/ml at 24 h immediately before the
medium change (Figure 1E). The same pattern of LIF level was
seen during the 24–48 h treatment period with the LIF levels
increasing linearly from undetectable at 0 h to 195 pg/ml by 48
h. Finally, in the third 24 h period, the LIF was undetectable after
the medium change and went up linearly to reach 290 pg/ml. As
observed, the final levels were higher each day, likely because the
number of tumor cells was increasing in the Transwell inserts.
Thus, myotubes incubated with C26 CM were exposed to higher
levels of LIF for a longer time compared to myotubes incubated
with Transwell inserts containing C26 cancer cells. In the case
of the one-time C26 CM addition, the average levels of LIF were
450, 410, and 370 pg/ml for the three 24 h periods. In the case of
the C26 Transwells, the levels of LIF halfway through each 24 h
period were 45, 125, and 180 pg/ml.
The Extent and Progression of Myotube
Atrophy Treated with Conditioned Medium
vs. Transwell® Inserts Containing Cancer
Cells
In order to determine the magnitude and progression of atrophy
when myotubes are exposed to LIF in the two cases, myotube
diameters were measured at 0, 24, 48, and 72 h of treatment
by either the bolus CM or the Transwell R© methods. Myotube
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FIGURE 1 | Cell culture models of tumor cell treated myotubes and the associated LIF levels in medium. (A) Schematic drawing of the design for the conventional
conditioned medium (CM) model. C26 cancer cells were incubated in differentiation medium (DM) for 24 h to produce conditioned medium. Four day-differentiated
C2C12 myotubes were treated for 72 h with 33% CM in fresh DM, refreshed every 24 h. (B) Photograph of a Transwell insert being placed into a well of a 6 well plate.
(C) Schematic diagram of the Transwell system with C26 cancer cells in the upper compartment and C2C12 4-day myotubes growing below (figure is redrawn from
Corning website). Cancer cells were seeded on microporous membrane insert (0.4 µm) placed into the well containing myotubes for 72 h with the upper and lower
compartments containing DM, refreshed every 24 h. (D) Graph of LIF levels in medium from myotube cultures treated with DM (control) or C26 CM at the beginning
and end of each 24 h period of treatment. (E) Graph of LIF levels in the lower compartment of myotube cultures with Transwell (TW) inserts seeded with C26 cells.
“Empty” indicates control myotube cultures containing Transwell inserts without C26 cells.
atrophy was 12, 19, and 11% (P < 0.05) due to treatment
with C26 CM at 24, 48, and 72 h, respectively, compared to
control myotubes incubated in DM only (Figure 2A). Myotube
atrophy was 18, 27, and 33% (P < 0.05) due to incubation
with Transwell R© inserts containing C26 cells at 24, 48, and
72 h, respectively, compared to control myotubes incubated
with Transwell R© inserts containing DM only with no cells
(Figure 2B).
In order to test myotube atrophy from a second mouse
tumor that is known for making high levels of LIF (Tomida
et al., 1984), Ehrlich ascites carcinoma cells were used in
the same two treatment designs as C26 to treat C2C12
myotubes. When exposed to CM made from Ehrlich ascites
carcinoma cells, myotube atrophy was 10, 14, and 10% at
24, 48, and 72 h, respectively (Figure 3A). In comparison,
when incubated with Transwell R© inserts containing Ehrlich
cells, myotube atrophy was 23, 31, and 37% at 24, 48,
and 72 h, respectively (Figure 3B). Therefore, in both mouse
carcinoma cell lines, there was a greater magnitude of atrophy
when myotubes were exposed to cancer cell containing
Transwell R© inserts compared to exposure to CM made from
cancer cells. Further, atrophy was progressively greater at
each time point when myotubes were incubated with cancer
cell containing Transwell R© inserts compared to incubation
with CM.
DISCUSSION
Skeletal muscle cells are deleteriously affected by tumor
secretions as is the case with skeletal muscle, a primary target
tissue in cancer cachexia. In fact, muscle loss, more than fat
loss or body weight loss is the strongest predictor of morbidity
and mortality (Martin et al., 2013). Prior to the present study,
the way to study cancer cell secretions on muscle in vitro
was to treat muscle cells in culture with solutions containing
tumor cell CM. In fact, medium from many tumor cells causes
wasting of cultured muscle cells, showing that tumor secreted
factors are sufficient to cause atrophy independent from the
host (Tisdale, 2009; Fearon et al., 2012). However, treatment of
cultured myotubes with these secretions in a bolus fashion differs
from the kinetics of tumor secretions and target tissue effects
in vivo. From the time that the tumor begins to grow, target
tissues are in continuous contact with secretions and the amounts
steadily increase as the tumors grow in size (Seto et al., 2015) and,
by metastasis, in number. Perhaps because the bolus addition
of cancer cell CM differs from delivery in vivo, the extent of
atrophy is less inmyotube culture than in wholemuscle in tumor-
bearing mice or in humans. In the present study, we incubated
myotubes with cancer cells contained in a compartment of the
well separated by a porous membrane and fluid space to more
closely recapitulate cachectic conditions in vivo, where the tumor
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FIGURE 2 | Myotube diameters in response to treatment with C26 CM or C26-Transwell inserts. (A) Treated with DM (control) or C26 CM for 72 h. DM or C26 CM
was refreshed every 24 h and photographs of the wells were taken just before feeding. Percent atrophy indicated for each treatment time point in graph. (B) Treated
with DM or Transwell inserts containing C26 tumor cells, medium refreshed every 24 h, again, photographs of the bottom wells taken just before feeding. On the right
of each graph are photographs of phase images of representative wells of control (top) and treated (bottom) myotubes at 72 h. *P < 0.05 compared to control value.
FIGURE 3 | Myotube diameters in response to treatment with Ehrlich tumor cell CM or Ehrlich-Transwell inserts. (A) Treated with DM (control) or Ehrlich CM for 72 h.
DM or Ehrlich CM was refreshed every 24 h, and photographs of the wells were taken just before feeding. Percent atrophy indicated for each treatment time point in
graph. (B) Treated with DM or Transwell inserts containing Ehrlich tumor cells, medium refreshed every 24 h, again, photographs of the bottom wells taken just before
feeding. To the right of each graph are photographs of phase images of representative wells of control (top) and treated (bottom) myotubes at 72 h. *P < 0.05
compared to control value.
cells and muscle fibers share a circulation but are not in contact.
We found that the magnitude and progression of atrophy in
myotubes exposed to cancer cells incubated in Transwell cultures
was similar to mouse cancer cachexia found in vivo (e.g., Bonetto
et al., 2011; Cornwell et al., 2014) and differed from myotubes
treated with a bolus of cancer cell CM.
We recently showed that the cytokine LIF is completely
responsible for myotube atrophy in a cell culture model of cancer
cachexia (Seto et al., 2015). Only a validated blocking antibody
against mouse LIF was able to inhibit C26 CM-induced C2C12
myotube atrophy, and it was 100% effective. In the present study,
we found that over the 72 h of myotube treatment with addition
of cancer cell CM, the LIF levels for each of the 3 successive
24-h treatment periods were higher over the entire period than
at any time when myotubes were incubated with cancer cells
plated on the Transwell insert. In the latter case, LIF levels began
near zero during each 24-h treatment period and were highest
at the end of the period before media replenishment. An average
value for the Transwell cultures would not compare to that for
the bolus treated cultures, since the LIF levels start each cycle
at 0 pg/ml, but LIF was never higher than 300 pg/ml and more
than half the time was <150 pg/ml. The levels of LIF for the
CM-treated cultures decreased slightly over each 24-h treatment
period, but were always >220 pg/ml. The rate of increase of LIF
in the Transwell cultures was 5, 8, and 12 pg/ml/h respectively for
each of the 24-h treatment periods. As a comparison to in vivo,
the increase in serum LIF during the final 6 days in C26 tumor-
bearing mice, during which almost all of the muscle atrophy
was found, amounted to 4 pg/ml per day (data from Seto et al.,
2015).
The extent of myotube atrophy in the two models supports
the idea that a constantly refreshed and increasing LIF delivery
is more important than the total LIF level in producing myotube
atrophy. Myotube atrophy was higher at each time point for the
Transwell treatment and continued to increase throughout the
72 h while the bolus produced its maximal atrophy at 48 h and
was less pronounced at 72 h. We interpret this to mean that
the slowly increasing and continuous LIF level in the Transwell-
containing plates is more effective at maintaining the pathways
for atrophy than a bolus addition of CM containing a high LIF
level. It is also possible that the large and sustained amount of
LIF in the bolus treatment is too much for normal LIF signaling
and causes downregulation of LIF receptors, but this is yet to be
directly tested. However, the lessening of atrophy during the last
24-h period in the bolus case appear to reflect less responsiveness
by the myotubes to the CM stimulus, which would be predicted
if receptors had been reduced. The fact that myotube atrophy
continued to increase over the 72 h of treatment with Transwell
inserts suggests this is a more physiological model of cancer
cachexia.
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There are no previous studies on the use of Transwells to study
tumor cell-induced muscle atrophy. There is a case in which
myoblasts have been incubated with fibroblasts in a Transwell
system thereby studying factors working in paracrine signaling
between the cells (e.g., Rao et al., 2013), to regulate myoblast
differentiation.
The most direct interpretation of the results in this study
is that tumor cells plated on Transwell inserts deliver LIF in a
continuously refreshed low to high dose pattern that is more
effective at stimulating and maintaining the muscle atrophy
exerted by tumors in a paracrine way. On the other hand, since
both tumor cells and skeletal muscle cells are in continuous
contact via the sharedmedium, there is the possibility that there is
a paracrine cross-talk between the cells. Factor/s from the muscle
cells might influence the secretions from the tumor to make
different factors affecting the muscle. However, we chose C26 for
this study because we have already shown that LIF explains all the
effect of this tumor on skeletal muscle myotube diameter in cell
culture (Seto et al., 2015). Furthermore, the difference inmyotube
atrophy between bolus and Transwell models was also observed
and data presented, using Ehrlich tumor cells. The Ehrlich mouse
tumor cells were the first identified source of LIF in a cancer
context (Tomida et al., 1984). In future studies, however, our
Transwell system makes a paracrine cross-talk study possible,
and may be applied for other cases of tumor cell-induced muscle
wasting.
The results presented here show that continuous delivery of
cachectic factors from tumor cells is the best way to produce
profound effects on skeletal muscle cell atrophy in cell culture
and this model should be considered in addition to CM
experiments, to dissect the tumor released factors responsible for
wasting.
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